Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 5/20 | 0.51 |
| ▸ | ABL1 | P00519 | 10/20 | 0.48 |
| ▸ | BCR | P11274 | 3/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | YES1 | P07947 | 1/20 | 0.48 |
| ▸ | LYN | P07948 | 1/20 | 0.48 |
| ▸ | HCK | P08631 | 1/20 | 0.48 |
| ▸ | FGR | P09769 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | SIK2 | Q9H0K1 | 10/20 | 0.44 |
| ▸ | SIK3 | Q9Y2K2 | 10/20 | 0.44 |
| ▸ | SIK1 | P57059 | 8/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14142362 | 0.88 | LCK (0.52) | LCKABL1BCRSRCMAPK13 | |
| SCHEMBL14141840 | 0.86 | LCK (0.50) | LCKABL1BCRSRCMAPK13 | |
| SCHEMBL12445981 | 0.86 | LCK (0.52) | LCKABL1BCRSRCMAPK13 | |
| SCHEMBL14141723 | 0.85 | LCK (0.51) | LCKABL1BCRSRCMAPK13 | |
| SCHEMBL14141667 | 0.83 | LCK (0.47) | LCKABL1BCRSRCMAPK13 | |
| SCHEMBL14142219 | 0.82 | LCK (0.47) | LCKABL1BCRSRCMAPK13 | |
| SCHEMBL27788358 | 0.78 | LCK (0.42) | LCKABL1BCRSRCMAPK13 | |
| SCHEMBL27788357 | 0.78 | LCK (0.42) | LCKABL1BCRSRCMAPK13 | |
| SCHEMBL13637396 | 0.77 | LCK (0.67) | LCKABL1BCRSRCMAPK13 | |
| SCHEMBL4254834 | 0.75 | LCK (0.52) | LCKABL1BCRSRCMAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108954-B2 | Synthesis process of dasatinib and intermediate thereof | NAN JING CAVENDISH BIO-ENGINEERING TECHNOLOGY CO., LTD. (CN) | 2015-08-18 | — | — | US | claimed |
| US-20130030177-A1 | SYNTHESIS PROCESS OF DASATINIB AND INTERMEDIATE THEREOF | Nan Jing Cavendish Bio-Engineering Technology Co. Ltd. (CN) | 2013-01-31 | — | — | US | claimed |
| EP-2532662-A1 | SYNTHESIS PROCESS OF DASATINIB AND INTERMEDIATE THEREOF | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2012-12-12 | — | — | EP | claimed |
| CN-101812060-B | Simple novel method for preparing high-purity Sprycel, and intermediate compound | NANJING CAVENDISH BIOENGINEERING TECHNOLOGY CO LTD | 2011-08-17 | — | — | CN | claimed |
| CN-101812060-A | Simple novel method for preparing high-purity Sprycel, and intermediate compound | NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD | 2010-08-25 | — | — | CN | claimed |
| US-9108954-B2 | Synthesis process of dasatinib and intermediate thereof | NAN JING CAVENDISH BIO-ENGINEERING TECHNOLOGY CO., LTD. (CN) | 2015-08-18 | — | — | US | disclosed |
| US-20130030177-A1 | SYNTHESIS PROCESS OF DASATINIB AND INTERMEDIATE THEREOF | Nan Jing Cavendish Bio-Engineering Technology Co. Ltd. (CN) | 2013-01-31 | — | — | US | disclosed |
| EP-2532662-A1 | SYNTHESIS PROCESS OF DASATINIB AND INTERMEDIATE THEREOF | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2012-12-12 | — | — | EP | disclosed |
| CN-101812060-B | Simple novel method for preparing high-purity Sprycel, and intermediate compound | NANJING CAVENDISH BIOENGINEERING TECHNOLOGY CO LTD | 2011-08-17 | — | — | CN | disclosed |
| CN-101812060-A | Simple novel method for preparing high-purity Sprycel, and intermediate compound | NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD | 2010-08-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030177-A1 | SYNTHESIS PROCESS OF DASATINIB AND INTERMEDIATE THEREOF | ABL1, YES1, ABL2 | LCK 73/4885ABL1 1/4885BCR 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.